prIME Masterclass in Head & Neck Cancer

Keeping Up to Date With Multidisciplinary Treatment Strategies

Not a member of My prIME? Join now for instant access.

Meeting Overview

Engage with the experts in the field of head & neck (H&N) cancer by joining this interactive one-day live meeting. Our experts will provide up-to-date insights into the current and emerging strategies in the management of H&N cancer, including targeted therapy, immunotherapy, and the latest advances in multidisciplinary management and molecular biology. Furthermore, you will learn how to optimally integrate new strategies into your patient care.

Date and Location

Saturday, 15 December 2018
08.00 – 17.00

Room: Leo
Le Méridien Taipei
38 Songren Road, Xinyi District
Taipei, Taiwan



Saturday, 15 December 2018
08.00 – 17.00



Taipei, Taiwan



Saturday, 15 December

08.00 Registration and welcome coffee
08.30 Welcome, introduction, and demographics
Pei-Jen Lou, MD, PhD, Frederic Peyrade, MD, and prIME Medical Director
08.40 Quiz: Test your expertise in H&N cancer
08.50 Setting the stage—Multimodality treatment approach in H&N cancer: Current standards, challenges, and unmet needs
Jin-Ching Lin, MD, PhD
09.15 Q & A
09.25 Advances in surgical management of squamous-cell carcinoma of the head & neck (SCCHN)
Jenn-Ren Hsiao, MD, PhD
09.50 Q & A
10.00 Coffee break
10.20 Interactive multidisciplinary tumor board: Early stage H&N cancer
Moderator: Pei-Jen Lou, MD, PhD
11.00 Keynote presentation—Reaching new heights in the management of H&N cancer: Evolving role of immunotherapy
Frederic Peyrade, MD
11.25 Q & A
11.35 Contemporary management of locally advanced SCCHN
Sadamoto Zenda, MD, PhD
12.00 Q & A
12.10 Induction therapy for locally advanced H&N cancer: Is there still a role?
Jin-Hyoung Kang, MD, PhD
12.35 Q & A
12.45 Lunch
13.45 Interactive multidisciplinary tumor board: Locally advanced SCCHN
Moderator: Pei-Jen Lou, MD, PhD
14.45 Optimal treatment of recurrent/metastatic SCCHN: Front-line therapy and beyond
Ye Guo, MD
15.10 Q & A
15.20 Interactive multidisciplinary tumor board: Recurrent/metastatic SCCHN
Moderator: Frederic Peyrade, MD
16.20 What can we expect in H&N cancer management in the near future?
Alexander Guminski, BSc, MBBS, FRACP, PhD
16.45 Quiz questions revisited
16.53 prIME Points™
Pei-Jen Lou, MD, PhD, and Frederic Peyrade, MD
17.00 Adjourn


  • Pei-Jen Lou, MD, PhDNational Taiwan University Hospital
    National Taiwan University College of Medicine
    Taipei, Taiwan
  • Frederic Peyrade, MDAntoine Lacassagne Center
    Nice, France
  • Faculty

  • Alexander Guminski, BSc, MBBS, FRACP, PhDNorthern Sydney Cancer Centre
    Royal North Shore Hospital
    Sydney, New South Wales, Australia
  • Ye Guo, MDTongji University, Shanghai East Hospital
    Shanghai, China
  • Jenn-Ren Hsiao, MD, PhDNational Cheng-Kung University Hospital
    Tainan, Taiwan
  • Jin-Hyoung Kang, MD, PhDCatholic University of Korea
    Seoul St Mary’s Hospital
    Seoul, South Korea
  • Jin-Ching Lin, MD, PhDTaichung Veterans General Hospital
    Taichung, Taiwan
  • Sadamoto Zenda, MD, PhDNational Cancer Center Hospital East
    Chiba, Japan

This educational activity is specifically designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals in Asia who are involved in the treatment of patients with H&N cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the importance of multidisciplinary care in H&N cancer and how to best apply it for optimal outcomes
  • Identify the current role of immunotherapy in the management of SCCHN and ongoing research strategies including combinations of conventional therapies and immunotherapies
  • Apply multidisciplinary approaches for managing patients with HPV+ and HPV- locally advanced SCCHN, elderly patients, and those unsuitable for platinum-based chemoradiation
  • Select optimal treatment sequence for patients with recurrent/metastatic SCCHN
  • Utilize current knowledge to manage complex clinical cases and toxicities related to the management of H&N cancer
  • Explain current and emerging therapeutic options for advanced SCCHN after progression on immunotherapy

This educational activity is endorsed by the Taiwan Head and Neck Society.

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA Statement

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.